昌吉测怀孕多久时间能测出来(昌吉阳痿治疗费用) (今日更新中)

The City of Glendale plans to vote on adding a permanent American flag to the top of Thunderbird Mountain. The Glendale Chamber Military and Veterans Affairs Committee sent a proposal to the city council asking to erect a flag. The committee will also manage it. Thunderbird Mountain falls within a conservation park, which means it is to be left as is. The picnic tables, garbage cans, and signage are all a part of the city's master plan, which is why they are allowed in the park. "We want people to enjoy it but not to disturb the wildlife the plants and not erect any structures in the park either, at least if they're not part of the master plan," said Vice-Mayor Lauren Tolmachoff. She is one of the council members voting to hold off on the change. "Not everybody on the council felt there was a conservation national park because there are signs and roads, and I disagree with that," she said. "You know there are roads in national parks, but they are still to be preserved and protected."No word on when the council will take an official vote, but it will likely be before the end of June.  1153

The Democratic National Committee contacted the FBI on Tuesday after it detected what it believes was the beginning of a sophisticated attempt to hack into its voter database, a Democratic source tells CNN.The DNC was alerted in the early hours of Tuesday morning by a cloud service provider and a security research firm that a fake login page had been created in an attempt to gather usernames and passwords that would allow access to the party's database, the source said.The page was designed to look like the access page Democratic Party officials and campaigns across the country use to log into a service called Votebuilder, which hosts the database, the source said, adding the DNC believed it was designed to trick people into handing over their login details.The source said the DNC is investigating who may have been responsible for the attempted attack, but that it has no reason to believe its voter file was accessed or altered.The DNC's chief security officer Bob Lord, a former Yahoo! executive, briefed Democrats on the attempted attack at a meeting of the Association of State Democratic Committees in Chicago on Wednesday.CNN has reached out to the FBI for comment.Early Tuesday morning, Microsoft announced that parts of an operation linked to Russian military intelligence targeting the US Senate and conservative think tanks that advocated for tougher policies against Russia were thwarted last week.That disclosure, coming less than three months ahead of the 2018 midterms, demonstrated Russia's continued efforts to destabilize US institutions. The news also places additional pressure on President Donald Trump to take action, even though he downplayed Russia's involvement as recently as Monday.The-CNN-Wire 1740

The contention around the 2020 presidential election is having some ripple effects, one of which is an effect on holiday shopping.Experts believe the delayed results are part of the reason there’s been a drop in holiday shopping, which retailers desperately need. So far, this year has been one of the toughest years for retail, especially brick and mortar stores.First, the pandemic forced closures and even as stores reopened, shoppers were initially hesitant to return to in-store shopping. Now, as holiday shopping starts to ramp up, the contentious presidential election has become a significant distraction for shoppers.“Consumers not knowing how to react have hit the pause button on their spending,” said Greg Portell, lead partner in the global consumer practice of Kearney.Portell believes without a clear winner in the presidential election and also acceptance of that victory, the holiday shopping season will not be what retailers needed.“The risk and uncertainty tied to civil unrest and the randomness of it at times, is really going to dampen consumers going into those locations,” said Portell. “That really takes the momentum out of what was a close recovery to what was traditional shopping patterns.”“Between the pandemic, the election,” said Mark Cohen, “it just doesn’t feel like we are going to have a jolly old Christmas.”Cohen, the Director of Retail Studies at the Columbia Business School, explained consumers need tranquility to spend and some excitement to spend the way they normally would for the holidays.“We’ve got a society of highly anxious, insecure, emotional, and battered consumers,” said Cohen, “None of that looks like it fits into any definition of tranquility.”However, some, like John Copeland with Adobe Analytics, caution against full doom and gloom around holiday shopping.“Typically, the day after an election, consumers slow their shopping a little bit,” said Copeland.Adobe Analytics data, gathered through its market-leading Adobe Analytics tool kit, shows in 2016 consumer spending dropped 14% after the election. After the 2018 midterms, it dropped 6%. So far, the day after this election, the drop was around 12%.However, those like Cohen and Portell expect, as the protests and legal battles over the election continue, even fewer people will want to spend money on shopping.If that starts to prove true, Copeland expects retailers will respond with new incentives for shoppers to start shopping at the “normal” holiday pace.“I think what we will see is retailers do more of what we already expect them to do which is pull their discounts and deals sooner into the season,” said Copeland. 2651

The Food and Drug Administration says it is re-examining the safety of a medication that was approved despite concerns that not enough was known about the drug's risks.In response to questioning at a budget hearing last week, FDA Commissioner Scott Gottlieb told members of Congress that he would "take another look" at Nuplazid, which is the only drug approved to treat hallucinations and delusions associated with Parkinson's disease psychosis.The medication has been cited as a so-called "suspect" medication in hundreds of deaths voluntarily reported by caregivers, doctors and other medical professionals since it hit the market, as highlighted in a recent CNN report.The FDA told CNN this week that the agency had already begun conducting a new evaluation of the medication when Gottlieb was questioned about it at the hearing. The agency said the review had started several weeks ago."What does it take for a drug like this to be taken off the market?" asked US Rep. Rosa DeLauro, a member and former chair of the congressional subcommittee responsible for funding and overseeing the FDA.DeLauro pressed Gottlieb for answers on his agency's response to the safety concerns surrounding Nuplazid."How many more adverse events do we have to have reported? How many people, quite frankly, have to die? Why does the industry always take precedence over public health and safety?"Tracked by the FDA, the adverse event reports cited by DeLauro do not mean that a suspected medication has been ruled the cause of harm and are typically not the result of official investigations. But the FDA uses the information to monitor potential issues with a drug and can take action as needed: updating a medication's label, for instance, or restricting its use. In rare cases, the agency can even pull a drug off the market.When asked by CNN about what prompted the FDA's new evaluation of Nuplazid, the agency said the decision was based on a number of factors but wouldn't say what those factors were. Instead, it would only comment generally, saying that it identifies "potential signals of serious risk/new safety information" in part by using adverse event data and that the agency is not suggesting physicians stop prescribing the drug or take patients off of it while a safety evaluation is taking place.The FDA has noted that the death reports citing Nuplazid have typically involved elderly patients with advanced-stage Parkinson's disease who suffered from numerous medical conditions and often take other medications that can increase the risk of death.But physicians, researchers and other medical experts told CNN that the high number of reports deserved a closer look to determine whether they were related to the drug. They also recommended further testing of Nuplazid, worrying that the drug had been approved too quickly, based on too little evidence that it was safe or effective.Nuplazid's review was expedited by the FDA because it had been designated a "breakthrough therapy," meaning it demonstrated "substantial improvement" in patients with serious or life-threatening diseases compared to treatments already on the market.Dr. Paul Andreason, the physician who led the FDA's medical review of Nuplazid, warned that patients taking the drug during the company's clinical trials experienced serious outcomes, including death, at more than double the rate of those taking the placebo. But the FDA ruled that the potential benefits outweighed the risks, agreeing with an advisory committee that cited a lack of safe alternatives and the pleas from family members who claimed the drug was already helping or could help their loved ones.At that advisory committee meeting two years ago, one woman said that her grandmother had been part of the clinical trials for the drug and that Nuplazid had been life-changing."We didn't know what to expect or even if she was on the drug" or a placebo, said Zoey Wade. "We soon realized that she must be taking the drug, because she really returned to herself. Her hallucinations reduced, and she better understood what was real and what was imaginary."Shortly after Nuplazid's release, however, patients' family members, doctors and other health care professionals started reporting "adverse events" possibly linked to the medication -- including deaths, life-threatening incidents, falls, insomnia, nausea and fatigue.During the first 10 months Nuplazid was on the market, 244 deaths were reported to the FDA in which Nuplazid was a "suspect" medication, according to an analysis conducted by the Institute for Safe Medication Practices. FDA data now show that the number of reported deaths has risen to more than 700. In more than 1,000 reports, patients continued to experience hallucinations while on Nuplazid.After CNN published its investigation on Nuplazid, reporters were contacted by family members who said the drug helped tame hallucinations with few apparent side effects and others who said they believe Nuplazid contributed to their family member's decline or death. Some said they had not yet reported these experiences to the drugmaker or the FDA.While the FDA has long been criticized for being too slow to approve drugs, DeLauro seized on its push to streamline the process, lambasting the agency for putting industry interests and efficiency above public health and safety.DeLauro described the number of adverse events and deaths as "staggering" and "unprecedented." She also expressed concern that the drugmaker, Acadia Pharmaceuticals, is attempting to get the drug approved for a larger population: patients who suffer from dementia-related psychosis."I don't know why it should stay on the market, especially when the FDA has not determined it to be safe and while the number of adverse events continues to soar," she told Gottlieb.In response to the congresswoman's remarks, Acadia told CNN that adverse event data alone are "not a comprehensive and accurate indicator of the safety profile of any drug." In response to CNN's earlier report on the drug, Acadia said there are a number of reasons for the higher volume of death reports, including the fact that the company distributes Nuplazid through a network of specialty pharmacies that puts the company in more frequent contact with both patients and caregivers -- meaning Acadia is more likely to receive reports of death, which it is required to pass along to the FDA.Commissioner Gottlieb told the committee that the FDA is careful about the decisions it makes and that there may be a higher tolerance for risk in situations where there is an unmet medical need, "so long as the patient is properly informed of what those risks are." This echoed what he told CNN's Dr. Sanjay Gupta in an interview earlier this month.The FDA previously told CNN that it was aware of Nuplazid's "complex safety profile" at the time of approval and required the drugmaker to place warnings on its labeling. The agency also said that, though it was continuing to monitor available information about Nuplazid, it had "not identified a specific safety issue" not already reflected on the medication's label.DeLauro's office told CNN that it plans to follow up with the FDA about its inquiry into Nuplazid. 7224

The election may be over but the term of President Donald Trump is not. So what can President Trump do between now and January 20, 2021?FIVE BIG AREASPresident Trump will likely be exploring options without Congress. The most obvious actions include the power to pardon, appoint top officials, fire top officials, approve military action and issue executive orders. President Trump could very well pardon anyone he wants, including former advisers Michael Flynn or Paul Manafort. President Trump may also explore the possibility of preemptively pardoning members of his own family as various investigations continue. HIRING AND FIRING President Trump has already begun the process of firing some top officials, including Secretary of Defense Mark Esper. President Trump may exercise that authority with other officials, such as the FBI Director who he has publicly criticized. The commander-in-chief may also continue to appoint top posts. He appears poised to confirm Judy Sheldon to the Federal Reserve before the end of his term, a position which has the power to influence interest rates and monetary policy for decades to come. EXECUTIVE ACTIONSPresident Trump will also continue to have authority to conduct military strikes since he is Commander-in-Chief. He will also have the ability to issue executive orders, although any order he issues could be immediately reversed when President-elect Biden takes office. 1428

来源：资阳报